165 related articles for article (PubMed ID: 21629335)
1. Effects of rapamycin on angiomyolipomas in patients with tuberous sclerosis.
Cabrera López C; Martí T; Catalá V; Torres F; Mateu S; Ballarín Castán J; Torra Balcells R
Nefrologia; 2011; 31(3):292-8. PubMed ID: 21629335
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus and tuberous sclerosis-associated renal angiomyolipomas.
Krischock L; Beach R; Taylor J
Arch Dis Child; 2010 May; 95(5):391-2. PubMed ID: 20457704
[TBL] [Abstract][Full Text] [Related]
3. Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex.
Peces R; Peces C; Cuesta-López E; Pérez-Dueñas V; Vega-Cabrera C; Azorín S; Selgas R
Nephrol Dial Transplant; 2010 Nov; 25(11):3787-91. PubMed ID: 20663789
[TBL] [Abstract][Full Text] [Related]
4. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex.
Wienecke R; Fackler I; Linsenmaier U; Mayer K; Licht T; Kretzler M
Am J Kidney Dis; 2006 Sep; 48(3):e27-9. PubMed ID: 16931204
[TBL] [Abstract][Full Text] [Related]
5. Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial.
Cabrera-López C; Martí T; Catalá V; Torres F; Mateu S; Ballarín J; Torra R
Orphanet J Rare Dis; 2012 Nov; 7():87. PubMed ID: 23140536
[TBL] [Abstract][Full Text] [Related]
6. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex.
Wang W; Guo H; Shi B; Sun H; Li H; Zhang Y; Cai Y
Int Urol Nephrol; 2019 Apr; 51(4):671-676. PubMed ID: 30756282
[TBL] [Abstract][Full Text] [Related]
7. Regression of renal angiomyolipomas with oral rapamycin therapy in a patient with tuberous sclerosis complex disease.
Torun D; Micozkadioglu H; Gedikoglu M; Ozelsancak R; Tekkarismaz N
Saudi J Kidney Dis Transpl; 2019; 30(2):545-548. PubMed ID: 31031395
[TBL] [Abstract][Full Text] [Related]
8. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis.
Hofbauer GF; Marcollo-Pini A; Corsenca A; Kistler AD; French LE; Wüthrich RP; Serra AL
Br J Dermatol; 2008 Aug; 159(2):473-5. PubMed ID: 18547304
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
Bissler JJ; McCormack FX; Young LR; Elwing JM; Chuck G; Leonard JM; Schmithorst VJ; Laor T; Brody AS; Bean J; Salisbury S; Franz DN
N Engl J Med; 2008 Jan; 358(2):140-51. PubMed ID: 18184959
[TBL] [Abstract][Full Text] [Related]
10. [Rapamycin in the treatment of renal diseases associated with tuberous sclerosis complex].
Dun S; Zou LP; Zhang MN; Wang YY; He W; Chen HM; Hu LY; Chen XQ; Lu Q; Pang LY; Liu LY; Tang LN; Wang B
Zhonghua Er Ke Za Zhi; 2019 Nov; 57(11):852-856. PubMed ID: 31665839
[No Abstract] [Full Text] [Related]
11. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.
Tarasewicz A; Debska-Slizień A; Konopa J; Zdrojewski Z; Rutkowski B
Transplant Proc; 2009 Nov; 41(9):3677-82. PubMed ID: 19917366
[TBL] [Abstract][Full Text] [Related]
12. Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response.
Truchuelo T; Díaz-Ley B; Ríos L; Alcántara J; Jaén P
Dermatol Online J; 2012 Jan; 18(1):15. PubMed ID: 22301052
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors.
Lam C; Bouffet E; Tabori U; Mabbott D; Taylor M; Bartels U
Pediatr Blood Cancer; 2010 Mar; 54(3):476-9. PubMed ID: 19856393
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic targeting of mTOR in tuberous sclerosis.
Sampson JR
Biochem Soc Trans; 2009 Feb; 37(Pt 1):259-64. PubMed ID: 19143643
[TBL] [Abstract][Full Text] [Related]
15. Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition.
Budde K; Gaedeke J
Am J Kidney Dis; 2012 Feb; 59(2):276-83. PubMed ID: 22130643
[TBL] [Abstract][Full Text] [Related]
16. Role of mTOR inhibition in the treatment of patients with renal angiomyolipomas.
Coombs EJ
J Am Assoc Nurse Pract; 2013 Nov; 25(11):588-96. PubMed ID: 24170533
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial.
Davies DM; de Vries PJ; Johnson SR; McCartney DL; Cox JA; Serra AL; Watson PC; Howe CJ; Doyle T; Pointon K; Cross JJ; Tattersfield AE; Kingswood JC; Sampson JR
Clin Cancer Res; 2011 Jun; 17(12):4071-81. PubMed ID: 21525172
[TBL] [Abstract][Full Text] [Related]
18. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease.
Dabora SL; Franz DN; Ashwal S; Sagalowsky A; DiMario FJ; Miles D; Cutler D; Krueger D; Uppot RN; Rabenou R; Camposano S; Paolini J; Fennessy F; Lee N; Woodrum C; Manola J; Garber J; Thiele EA
PLoS One; 2011; 6(9):e23379. PubMed ID: 21915260
[TBL] [Abstract][Full Text] [Related]
19. The effect of sirolimus on angiomyolipoma is determined by decrease of fat-poor compartments and includes striking reduction of vascular structures.
Watanabe EH; Coelho FMA; Filho HL; Balbo BEP; Neves PDMM; Franzin FM; Yamauchi FI; Onuchic LF
Sci Rep; 2021 Apr; 11(1):8493. PubMed ID: 33875750
[TBL] [Abstract][Full Text] [Related]
20. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients.
Foster RS; Bint LJ; Halbert AR
Australas J Dermatol; 2012 Feb; 53(1):52-6. PubMed ID: 22309333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]